QNCX (Quince Therapeutics, Inc.) Earnings per share for the last four quarters

Quince (QNCX) - corporate logo

Quince Therapeutics (QNCX) integrates environmental standards and ethics into the development of metabolic drugs. This trading chart demonstrates an EPS TTM of 42.40. The operating model relies on external contractors who handle all stages of synthesis and testing. Meanwhile, Quince Therapeutics (QNCX) is developing an innovative AOC system for drug transport via erythrocytes, aiming to capture the niche of rare pathologies.

QNCX quincetx.com Net earnings per share (EPS TTM) (02/11/2024 - 10/12/2026)

QNCX (quincetx.com): analytical breakdowns and indicator data

- business market valuation indicators:
Fundamental company valuation:QNCX (Quince)
Core merchandise of Quince Therapeutics

This indicator measures the percentage change in net earnings per share over a rolling twelve-month period, reflecting the efficiency of capital generation relative to historical performance. By analyzing the annual EPS growth based on trailing twelve months (TTM) financial statements, an investor assesses the monetization of innovations by Quince Therapeutics (QNCX) in the field of orphan disease treatment and the biotech brand's ability to transform scientific potential into tangible financial results.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months biomeafusion.com (BMEA)|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS